Cargando…

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19

Detalles Bibliográficos
Autores principales:	Zacharias, Harry, Mungara, Ritwik, Wilson, Andrew Peter, Singer, Mervyn, Arulkumaran, Nishkantha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098225/ https://www.ncbi.nlm.nih.gov/pubmed/35569216 http://dx.doi.org/10.1016/j.jcrc.2022.154053

Ejemplares similares

Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
por: Snow, Timothy Arthur Chandos, et al.
Publicado: (2021)

Immunomodulators in COVID-19: Two Sides to Every Coin
por: Snow, Timothy A. C., et al.
Publicado: (2020)

Use of non-invasive ventilation for patients with COVID-19: a cause for concern?
por: Arulkumaran, Nishkantha, et al.
Publicado: (2020)

Risk factors associated with bloodstream infections among critically ill patients with COVID-19
por: McMillan, Tim, et al.
Publicado: (2021)

Association Between Hypocholesterolemia and Mortality in Critically Ill Patients With Sepsis: A Systematic Review and Meta-Analysis
por: Hofmaenner, Daniel A., et al.
Publicado: (2023)

The Pharmacology and Therapeutic Utility of Sodium Hydroselenide
por: Samra, Kavitej, et al.
Publicado: (2021)

Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
por: Camou, Fabrice, et al.
Publicado: (2022)

Creating complex protocells and prototissues using simple DNA building blocks
por: Arulkumaran, Nishkantha, et al.
Publicado: (2023)

Inhaled nitric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome
por: Longobardo, Alessia, et al.
Publicado: (2021)

“L'histoire se répète”, one size does not fit all. Author’s reply
por: Snow, Timothy Arthur Chandos, et al.
Publicado: (2021)

Clarithromycin as an immunomodulator in sepsis: still a (IN)CLASS act
por: Snow, Timothy Arthur Chandos, et al.
Publicado: (2022)

COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study
por: Longobardo, Alessia, et al.
Publicado: (2021)

Steroids in ARDS: more light is being shed
por: Arulkumaran, Nishkantha, et al.
Publicado: (2020)

Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19
por: Snow, Timothy Arthur Chandos, et al.
Publicado: (2022)

Is the inflammasome a potential therapeutic target in renal disease?
por: Turner, Clare M, et al.
Publicado: (2014)

Critical illness and flat batteries
por: Singer, Mervyn
Publicado: (2017)

Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression
por: Snow, Timothy A.C., et al.
Publicado: (2021)

Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab
por: Rashad, Alaa, et al.
Publicado: (2021)

Purinergic signaling in inflammatory renal disease
por: Arulkumaran, Nishkantha, et al.
Publicado: (2013)

Antimicrobial-associated harm in critical care: a narrative review
por: Arulkumaran, Nishkantha, et al.
Publicado: (2020)

Tocilizumab in critically ill COVID-19 patients: An observational study
por: Mushtaq, Muhammad Z., et al.
Publicado: (2022)

Butyrate Supplementation Exacerbates Myocardial and Immune Cell Mitochondrial Dysfunction in a Rat Model of Faecal Peritonitis
por: Peters, Vera B. M., et al.
Publicado: (2022)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Treating Critical Illness: The Importance of First Doing No Harm
por: Singer, Mervyn, et al.
Publicado: (2005)

Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19
por: Hashimoto, Shoji, et al.
Publicado: (2021)

Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
por: Bhandari, Sudhir, et al.
Publicado: (2021)

Multi-Organ Dysfunction in the Critically Ill: Effects on Different Organs
por: Brealey, David, et al.
Publicado: (2000)

Multi-Organ Dysfunction in the Critically Ill: Epidemiology, Pathophysiology and Management
por: Brealey, David, et al.
Publicado: (2000)

Renal Tubular Cell Mitochondrial Dysfunction Occurs Despite Preserved Renal Oxygen Delivery in Experimental Septic Acute Kidney Injury
por: Arulkumaran, Nishkantha, et al.
Publicado: (2018)

Dexamethasone/methylprednisolone/tocilizumab: Candidaemia: case report
Publicado: (2021)

Cholesterol and its association with muscle weakness in critical illness
por: Hofmaenner, Daniel A., et al.
Publicado: (2021)

Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
por: Szabo, Robert, et al.
Publicado: (2023)

Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia
por: AlQahtani, Hajar, et al.
Publicado: (2022)

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
por: Elhazmi, Alyaa, et al.
Publicado: (2023)

Plasma exchange for COVID‐19 thrombo‐inflammatory disease
por: Arulkumaran, Nishkantha, et al.
Publicado: (2020)

Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
por: Hong, Jin Yeong, et al.
Publicado: (2022)

Learning for the next pandemic: the Wuhan experience of managing critically ill people
por: Du, Bin, et al.
Publicado: (2021)

Dexamethasone: A boon for critically ill COVID-19 patients?
por: Patel, Shailesh Kumar, et al.
Publicado: (2020)

Relationship between CRP and hypofibrinolysis: Is this a possible mechanism to explain the association between CRP and outcome in critically ill patients?
por: Zouaoui Boudjeltia, Karim, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_ilhcu8l2c39bflor4iphkveubt